Brokerages forecast that DelMar Pharmaceuticals Inc (NASDAQ:DMPI) will report earnings of ($0.10) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals reported earnings of ($0.18) per share in the same quarter last year, which indicates a positive year over year growth rate of 44.4%. The firm is scheduled to announce its next quarterly earnings results on Friday, May 11th.
On average, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.46) per share for the current fiscal year. For the next year, analysts forecast that the business will report earnings of ($0.26) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover DelMar Pharmaceuticals.
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01.
Shares of DelMar Pharmaceuticals (DMPI) traded down $0.04 during trading hours on Monday, reaching $1.10. 64,434 shares of the company were exchanged, compared to its average volume of 760,171. The firm has a market cap of $24.63, a PE ratio of -1.59 and a beta of 1.29. DelMar Pharmaceuticals has a 12-month low of $0.78 and a 12-month high of $5.20.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP acquired a new position in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned about 1.69% of DelMar Pharmaceuticals as of its most recent filing with the SEC. 5.50% of the stock is currently owned by institutional investors and hedge funds.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.